Ophthalmic Biomaterials And Drug Delivery Systems

眼科生物材料和药物输送系统

• 批准号: CRC-2014-00118
• 负责人: Sheardown, Heather
• 金额: $ 7.29万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Canada Research Chairs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=729541
• 关键词: Ophthalmic; Biomaterials; Drug; Delivery; Systems

Diseases of the eye represent a significant and increasing burden to society. The cost of vision loss in Canada in 2009 was estimated to be $15.8 B; the number of people living with vision loss is currently more than 1M, more than breast cancer, prostate cancer, Alzheimers and Parkinson's disease combined. This number is expected to double over the next 25 years. Not only does eye disease impact the ability to see, it can have a significant effect on quality of life. The ability to effectively deliver drugs has been suggested as the greatest unmet need in ophthalmology. The chair will focus on developing ocular drug delivery materials and surfaces. Using the high throughput synthesis and characterization to generate libraries of materials, Dr. Sheardown will be able to screen large numbers of materials and ultimately develop the next generation of ophthalmic materials.

眼部疾病代表了社会的显著且日益增加的负担。2009年，加拿大视力丧失的成本估计为158 B美元;目前视力丧失的人数超过100万，超过乳腺癌，前列腺癌，阿尔茨海默病和帕金森病的总和。 预计这一数字在未来25年内将翻一番。 眼疾不仅影响视力，还可能对生活质量产生重大影响。 有效递送药物的能力已被认为是眼科学中最大的未满足的需求。 该主席将专注于开发眼部药物输送材料和表面。 使用高通量合成和表征来生成材料库，Sheardown博士将能够筛选大量材料，并最终开发下一代眼科材料。